Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review
Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging
evidence suggests common mechanisms between cancer and cardiovascular disease …
evidence suggests common mechanisms between cancer and cardiovascular disease …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Dual Antiplatelet therapy and cancer; balancing between ischemic and bleeding risk: a narrative review
G Tsigkas, A Vakka, A Apostolos, E Bousoula… - Journal of …, 2023 - mdpi.com
Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk
factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the …
factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the …
Management of acute coronary syndrome in cancer patients: it's high time we dealt with it
F Luca, I Parrini, MG Abrignani, CM Rao… - Journal of Clinical …, 2022 - mdpi.com
Cancer patients have an increased risk of cardiovascular disease and, notably, a significant
prevalence of acute coronary syndrome (ACS). It has been shown that an elevated presence …
prevalence of acute coronary syndrome (ACS). It has been shown that an elevated presence …
Gender differences in long-term outcomes of young patients who underwent percutaneous coronary intervention: Long-term outcome analysis from a multicenter …
Young patients who underwent percutaneous coronary intervention (PCI) have shown
worse long-term outcomes but remain inadequately investigated. We analyzed 1,186 …
worse long-term outcomes but remain inadequately investigated. We analyzed 1,186 …
Outcomes of patients with myeloproliferative neoplasms admitted with myocardial infarction: insights from National Inpatient Sample
Abstract Background Myeloproliferative neoplasms (MPNs) are hematopoietic stem cell
neoplasms with a high risk of thrombosis, including acute myocardial infarction (AMI) …
neoplasms with a high risk of thrombosis, including acute myocardial infarction (AMI) …
[HTML][HTML] Prognosis of acute coronary syndrome stratified by cancer type and status-a nationwide cohort study
N Nouhravesh, JE Strange, J Tønnesen, A Holt… - American Heart …, 2023 - Elsevier
Background To investigated the prognosis of the most prevalent cancers (breast-,
gastrointestinal-, and lung cancer), according to cancer status (ie, active-, non-active …
gastrointestinal-, and lung cancer), according to cancer status (ie, active-, non-active …
Ischaemic heart disease in patients with cancer
Cardiologists are encountering a growing number of cancer patients with ischaemic heart
disease (IHD). Several factors account for the interrelationship between these two …
disease (IHD). Several factors account for the interrelationship between these two …
Cardiovascular safety assessment in cancer drug development
O Oren, TG Neilan, MG Fradley… - Journal of the American …, 2021 - Am Heart Assoc
The development of cardiovascular toxicity attributable to anticancer drugs is a pivotal event
that is associated with cardiovascular morbidity as well as with worse cancer‐specific and …
that is associated with cardiovascular morbidity as well as with worse cancer‐specific and …
The year in cardiovascular medicine 2021: cardio-oncology
J Herrmann, T López-Fernández… - European heart …, 2022 - academic.oup.com
Publications in cardio-oncology have increased exponentially over the past two decades.
The Year in Cardiovascular Medicine: Cardio-Oncology 2020–21 covers the most recent …
The Year in Cardiovascular Medicine: Cardio-Oncology 2020–21 covers the most recent …